VJOncology is committed to improving our service to you

ESMO 2019 | PD1 & PDL1 inhibitors for mUC, where are we?

VJOncology is committed to improving our service to you

Petros Grivas

Petros Grivas, MD, PhD, Seattle Cancer Care Alliance, Seattle, WA, outlines efficacy and safety data on the use of PD1 & PDL1 inhibitors in the treatment of metastatic urothelial cancer (mUC) at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter